The Global Health Body Issues Alert Over Acute Scarcity of Obesity Jabs
Under a tenth of individuals who could benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it releases its first advice on the medications.
With more than one billion people worldwide currently obese, it is urging broader and more equitable access to this class of drugs.
According to forecasts, over two billion will be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major obstacles to widespread access to the injections that can aid individuals in losing substantial body mass, explains the organization.
Weight-Loss Drug Scarcity
Even under the present most optimistic scenario, the supply of these medications could only cover approximately 100 million people – less than 10% of the global need, according to the WHO.
The advice urges countries and companies to increase availability, by approaches including voluntary licensing.
Exclusive production rights on semaglutide – the core component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Work
These medications mimick a natural hormone to slow digestion, suppress the appetite and enhance feelings of fullness so people consume fewer calories.
Patients commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Evidence points to people may see weight return after a year of stopping the treatment, when their typical food cravings resume.
Being overweight or obese elevates your risk for contracting medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects people in all nations and was responsible for millions of deaths worldwide in 2024, according to the WHO.
